急性缺血性脑卒中患者应用替罗非班致血小板减少一例报道

Thrombocytopenia Caused by Tirofiban in a Patient with Acute Ischemic Stroke

替罗非班是一种可逆性非肽类血小板糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂,因具有t1/2短、起效快、过程可逆且安全性高等优势而广泛用于抑制血小板形成。既往研究表明,替罗非班治疗急性缺血性脑卒中安全、有效,而本文报道了1例应用替罗非班1 h后出现极重度血小板减少的急性缺血性脑卒中患者,旨在提高临床医生对替罗非班所致血小板减少的认识。

Tirofiban,as one kind of reversible and non-peptide platelet GP Ⅱ b/Ⅲ a receptor antagonists,is widely used to inhibit the platelet formation due to its short t1/2,rapid onset,reversible process and high safety. Previous studies have shown that,tirofiban is safe and effective in the treatment of acute ischemic stroke,however this paper reported an acute ischemic stroke patient with severe thrombocytopenia caused by tirofiban,in order to improve the understanding of thrombocytopenia caused by tirofiban on clinic.